Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Best Conduits and Best Surgeons for the Best Outcome

Myocardial revascularization surgery is still one of the most effective treatment strategies against coronary disease. One of the most important advantages of surgery over angioplasty is the chance to reach complete revascularization. This has proven to improve the survival of patients and to reduce the number of cardiovascular events.

Tasa de stroke post cirugía vs angioplastia coronaria en un análisis de más de 10.000 pacientes

The choice of conduit for the grafts is critical to ensure their patency (ultimately, to ensure complete revascularization for a longer time).

Given the accelerated decay of vein grafts (50% are occluded at 10 years), the internal thoracic artery has become the gold standard to connect the anterior descending artery.

However, the use of arterial grafts from an artery other than the internal thoracic artery is very low. The bilateral internal thoracic artery is used in around 4.9% of cases, and the radial artery is used in 6.5% of cases.


Read also: Do Polymers Play any Role in Drug Eluting Stents.


The lack of adoption of full arterial revascularization is partially due to a lack of solid, unequivocal evidence on its benefit.

While several series and meta-analysis have shown the benefit of arterial revascularization, recent randomized studies have not been able to do so. This means that there is no solid evidence justifying its higher technical difficulty, its higher procedural time, and its potential complications.

This study, published in J Am Coll Cardiol, included an impressive group of 61,310 patients who underwent coronary artery bypass graft surgery with a single arterial graft (n = 49,076; 80%) or multiple arterial grafts (n = 12,234; 20%). Authors used propensity score matching to reduce the differences between groups. At 1 year, there were no differences between strategies, but at 7 years, the rates of mortality, infarction, and new revascularization were significantly lower in the multiple arterial grafts group.

The greatest strength of this study is the huge number of patients enrolled in 42 hospitals and with 246 surgeons, which can paint a realistic picture of daily clinical practice.



Read also: TAVR in Bicuspid Has the Same Results in Surgery at Hospital Level.


The lowest mortality rates in the multiple arterial grafts group were found in the most experienced sites as regards this strategy.

Another important piece of information is that arterial grafts were significantly associated with wound infections.

Conclusion

The rates of mortality and combined events at 1 year were similar between surgery with a single arterial graft and multiple arterial grafts. However, at 7 years, multiple arterial grafts showed clear benefit from all points of view.

Original title: Multiple Versus Single Arterial Coronary Bypass Graft Surgery for Multivessel Disease.

Reference: Zaza Samadashvili et al. J Am Coll Cardiol 2019;74:1275–85.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...